Acute Myeloid Leukemia
Show Only Open Trials
1.
Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
2.
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Plexxikon
3.
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML) with Core Binding Factor Abnormaility
- Protocol ID: CALGB 10801
4.
CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: FLT3 Mutated Acute Myeloid Leukemia
5.
CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia
6.
NCI 8977: Phase 2 Trial of R11577 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
- Study Status: Open to Enrollment
- Sponsor: National Cancer Institute
- Disease Status and/or Stage: Acute Myeloid Leukemia
7.
A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or High-risk Myelodysplasia (MDS)
8.
Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematological Malignancies
9.
A Phase I/II Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)
- Study Status: Open to Enrollment
- Sponsor: New York Cancer Consortium; National Cancer Institute
- Disease Status and/or Stage: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukemia
10.
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
- Study Status: Open to Enrollment
- Sponsor: Sunesis Pharmaceuticals
- Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
11.
A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia
- Study Status: Open to Enrollment
- Sponsor: Clavis Pharma
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
12.
A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Study Status: Open to Enrollment
- Sponsor: SuperGen
- Disease Status and/or Stage: Intermediate-2 or high-risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
13.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Closed to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
